Estimation and Comparison of Pro-BNP level in patient with Heart Failure due to COPD and LV dysfunction
Keywords:
Congestive heart failure (CHF), Left ventricular dysfunction (LVD), Pro BNP, Chronic obstructive pulmonary airway disease (COPD), Ischemic heart disease (IHD)Abstract
Introduction: Diagnosis of heart failure and chronic obstructive pulmonary disease remains predominantly clinical decision. Many times both the condition may mimic each other and differentiation may be difficult specially in elderly and obese individuals. Pro-BNP is an important marker to distinguish the above conditions. We did a study to estimate and compare the levels of Pro-BNP in patients with heart failure due to COPD and LV dysfunction. Material and methods: The study subjects were 60 patients of comparable age group admitted in department of medicine and cardiology. Level of pro BNP was assessed using Immune electro chemiluminescence assay (IECMA). Results: The mean level of pro BNP was significantly raised in patients with heart failure due to LV dysfunction. Left Ventricular Ejection Fraction and levels of Pro BNP were not related. Conclusion: Pro BNP can serve as a good clinical tool in differentiation of dyspnea arising out of congestive heart failure and chronic obstructive pulmonary airway diseases specially in elderly and obese patients. It is easy to perform and bedside test.
References
Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5:167–173
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart Disease and Stroke Statistics-2011 update: A report from the American Heart Association. Circulation 2011; 123: 18-209.
Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham study. J Am coll cardiol. 1993; 22: 6A-13A.
McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998; 19 Suppl P:P9.
Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25:1614
Velagaleti R, Vasan RS. Heart in the 21st century: is it a coronary artery disease problem or hypertension problem? Cardiol clin. 2007; 25:487-95
Bourassa MG, Gurne O, Bangbiwala SI,et al. Natural history and pattern of current practise in heart failure. The studies of left ventricular dysfunction (SOLVD) investigators. J Am Coll cardiol 1993:22:14A-19 .
Cowie MR, Stmthers AD, Wood DA. et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350:1347-1351
J Am coll Cardiol. 2004 Aug 18; 44(4): 740-9. Measuring plasma B-type natriuretic peptide in heart failure:
Cheung BMY, Kumana CR. Natriuretic peptidesrelevance in cardiac disease. JAMA. 1998;280:1983– 1984.
Redfield MM, Jacobson SJ, Burnett JCjr, et al. Burden of systolic and diastolic ventricular
Dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202
Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid Bnatriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39(2):202–209.
Yasue K Yoshimura M, Jougasaki M, Itoh H, Suga S, Ogawa Y Nakao K. Plasma levels of brain natriuretic peptide in normal subjects and patients with chronic heart failure: measurement by immunoradiometric assay (IRMA) Horm Clin. 1993; 41:397-407.
Jong p, vowinckel E , Liu PP, et al. Prognosis and determinant of survival in patient s newly hospitalized for heart failure: a population based study. Arch Intern med. 2002;162:1689-94.
Roger VL, Weston SA, Redfield MM, et al. Trands in heart failure incidence and survival in a community based population. JAMA. 2004,292:344-50.
Dao Q. Krishnaswamy P. Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coli Cardiol 2001:37:379-85.
A.Mark Richards, M. Carry Nicholls et al : BNP and LVEF are complementary independent predictor of major adverse events on follow up after myocardial infarction (Circulation 2003 ; 107; 2786-2792).
Matusno K, Nishi kimi T, Yutani C et al . Diagnostic value of plasma level of BNP in arrhythmogenic right ventricular dysplasia, (J.M. Cardiol; 31;202-208.
Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440-4.
Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:202–208
Jensen KT, Carstens J, Ivarsen P, Pendersen EB. A new, fast and reliable radioimmunossay of brain Natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab invest 1997; 57:529-540.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Biomedical Review follows the Creative Commons CC-BY license (Attribution). It means Authors can use, reuse and build upon the material published in the journal but only for non-commercial purposes. Every article published in the Journal clearly mentioned licensing terms between author/authors and publisher (Siddharth Health Research and Social Welfare Society) as the logo of Creative Commons CC-BY license (Attribution) https://creativecommons.org/licenses/by/4.0/.